MicroRNA-320a promotes 5-FU resistance in human pancreatic cancer cells

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wang, Weibin ^a   Zhao, Lijun ^b,c   Wei, Xueju ^b,c   Wang, Lanlan ^b,c   Liu, Siqi ^b   Yang, Yu ^a   Wang, Fang ^b   Sun, Guotao ^c   Zhang, Junwu ^b   Ma, Yanni ^b   Zhao, Yupei ^a   Yu, Jia ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c HENAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; APOPTOSIS REGULATORY PROTEIN; FLUOROURACIL; MICRORNA; MIRN320 MICRORNA, HUMAN; PDCD4 PROTEIN, HUMAN; RNA BINDING PROTEIN;

3' UNTRANSLATED REGION; CELL MOTION; CELL PROLIFERATION; DOWN REGULATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM; PANCREAS TUMOR; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; MICRORNAS; PANCREATIC NEOPLASMS; RNA-BINDING PROTEINS;

EID: 84974623061     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep27641     Document Type: Article

References (36)

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J Clin 63, 11-30, doi: 10.3322/caac.21166 (2013).
2. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J Clin 60, 277-300, doi: 10.3322/caac.20073 (2010).
3. Chen, W. et al. Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res 25, 10-21, doi: 10.3978/j. issn.1000-9604.2012.12.04 (2013).
4. Gottesman, M. M. Mechanisms of cancer drug resistance. Annu Rev Med 53, 615-627, doi: 10.1146/annurev.med.53.082901. (2002).
5. Hermann, P. C. et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323, doi: 10.1016/j.stem.2007.06.002 (2007).
6. Karamitopoulou, E. Role of epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma: is tumor budding the missing link? Front Oncol 3, 221, doi: 10.3389/fonc.2013.00221 (2013).
7. Jiang, J. H. et al. Epithelial-mesenchymal transition in pancreatic cancer: Is it a clinically significant factor? Biochim Biophys Acta 1855, 43-49, doi: 10.1016/j.bbcan.2014.11.004 (2015).
8. Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2, 442-454, doi: 10.1038/nrc822 (2002).
9. Sabbah, M. et al. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat 11, 123-151, doi: 10.1016/j.drup.2008.07.001 (2008).
10. Liu, J., Valencia-Sanchez, M. A., Hannon, G. J. & Parker, R. MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol 7, 719-723, doi: ncb1274 (2005).
11. Saxena, S., Jonsson, Z. O. & Dutta, A. Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J Biol Chem 278, 44312-44319, doi: 10.1074/jbc.M307089200 (2003).
12. Gironella, M. et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 104, 16170-16175, doi: 0703942104 (2007).
13. Iorio, M. V. et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65, 7065-7070, doi: 65/16/7065 (2005).
14. Takamizawa, J. et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64, 3753-3756, doi: 10.1158/0008-5472 (2004).
15. Le, X. F., Merchant, O., Bast, R. C. & Calin, G. A. The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. Cancer Microenviron 3, 137-147, doi: 10.1007/s12307-010-0037-4 (2010).
16. Cano, A. & Nieto, M. A. Non-coding RNAs take centre stage in epithelial-to-mesenchymal transition. Trends Cell Biol 18, 357-359, doi: 10.1016/j.tcb.2008.05.005 (2008).
17. Garzon, R., Fabbri, M., Cimmino, A., Calin, G. A. & Croce, C. M. MicroRNA expression and function in cancer. Trends Mol Med 12, 580-587, doi: S1471-4914(06)00242-5 (2006).
18. Fang, Z. et al. Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. J Exp Clin Cancer Res 34, 86, doi: 10.1186/s13046-015-0198-6 (2015).
19. Sun, L. et al. MiR-320a acts as a prognostic factor and Inhibits metastasis of salivary adenoid cystic carcinoma by targeting ITGB3. Mol Cancer 14, 96, doi: 10.1186/s12943-015-0344-y (2015).
20. Yang, A. D. et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 12, 4147-4153, doi: 12/14/4147 (2006).
21. Hiscox, S. et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer 118, 290-301, doi: 10.1002/ijc.21355 (2006).
22. Ponti, D., Zaffaroni, N., Capelli, C. & Daidone, M. G. Breast cancer stem cells: an overview. Eur J Cancer 42, 1219-1224, doi: S0959- 8049(06)00179-1 (2006).
23. Soltysova, A., Altanerova, V. & Altaner, C. Cancer stem cells. Neoplasma 52, 435-440 (2005).
24. Fuchs, B. C. et al. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 68, 2391-2399, doi: 10.1158/0008-5472 (2008).
25. Cheng, G. Z. et al. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 67, 1979-1987, doi: 67/5/1979 (2007).
26. Zhang, Y. et al. microRNA-320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer. Oncol Rep 27, 685-694, doi: 10.3892/or.2011.1561 (2012).
27. Yao, J. et al. GNAI1 Suppresses Tumor Cell Migration and Invasion and is Post-Transcriptionally Regulated by Mir-320a/c/d in Hepatocellular Carcinoma. Cancer Biol Med 9, 234-241, doi: 10.7497/j.issn.2095-3941.2012.04.003 (2012).
28. Liu, N. et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol 13, 633-641, doi: 10.1016/S1470-2045(12)70102-X (2012).
29. Lima, R. T. et al. MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer 47, 163-174, doi: 10.1016/j.ejca.2010.11.005 (2011).
30. Schoof, C. R., Botelho, E. L., Izzotti, A. & Vasques Ldos, R. MicroRNAs in cancer treatment and prognosis. Am J Cancer Res 2, 414-433 (2012).
31. Osman, A. MicroRNAs in health and disease-basic science and clinical applications. Clin Lab 58, 393-402 (2012).
32. Fillat, C. & Altafaj, X. Gene therapy for Down syndrome. Prog Brain Res 197, 237-247, doi: 10.1016/B978-0-444-54299-1.00012-1 (2012).
33. Wan, L. Y. et al. miR-320 enhances the sensitivity of human colon cancer cells to chemoradiotherapy in vitro by targeting FOXM1. Biochem Biophys Res Commun 457, 125-132, doi: 10.1016/j.bbrc.2014.11.039 (2015).
34. Ma, G. et al. Downregulation of programmed cell death 4 (PDCD4) in tumorigenesis and progression of human digestive tract cancers. Tumour Biol 34, 3879-3885, doi: 10.1007/s13277-013-0975-9 (2013).
35. Wei, X. et al. MicroRNA-21 induces 5-fluorouracil resistance in human pancreatic cancer cells by regulating PTEN and PDCD4. Cancer Med, doi: 10.1002/cam4.626 (2016).
36. P., M. R. et al. Inhibition of NF-kappaB by deoxycholic acid induces miR-21/PDCD4-dependent hepatocelular apoptosis. Sci Rep 5, 17528, doi: 10.1038/srep17528 (2015).